Pathogenesis of Hypertension

Hypertension: A Companion to Braunwald's Heart Disease: Second Edition

Volumn , Issue , 2013, Pages 12-26

  Acelajado, Maria Czarina ^a   Calhoun, David A ^b   Oparil, Suzanne ^b  

^a UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^b University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904239051     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-2766-1.00002-8     Document Type: Chapter

References (67)

1. Pimenta E., Calhoun D.A., Oparil S. Etiology and pathogenesis of systemic hypertension. Cardiology 2010, 511-522. Mosby, Philadelphia, PA. 3rd ed. M.H. Crawford, J.P. DiMarco, W.J. Paulus (Eds.).
2. Franco V., Calhoun D.A., Oparil S. Pathophysiology of hypertension. Hypertension: A Companion to Braunwald's Heart Disease 2007, 25-46. WB Saunders, Philadelphia, PA. 1st ed. H.R. Black, W.J. Elliott (Eds.).
3. Alberti K.G.M.M., Eckel R.H., Grundy S.M., et al. Harmonizing the metabolic syndrome. A joint interim statement from the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation, International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
4. Grassi G., Dell'Oro R., Facchini A., et al. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens 2004, 22:2363-2369.
5. Pimenta E., Calhoun D.A., Oparil S. Sleep apnea, aldosterone and resistant hypertension. Prog Cardiovasc Dis 2009, 51:371-380.
6. Tilg H., Moschen A.R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006, 6:772-783.
7. Considine R.V. Human leptin: an adipocyte hormone with weight-regulatory and endocrine functions. Semin Vasc Med 2005, 5:15-24.
8. Vecchione C., Arretini A., Maffei A., et al. Cooperation between insulin and leptin in the modulation of vascular tone. Hypertension 2003, 42:166-170.
9. Katagiri H., Yamada T., Oka Y. Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Circ Res 2007, 101:27-39.
10. Yilmaz M.I., Sonmez A., Caglar K., et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton) 2007, 12:147-153.
11. Ohashi K., Kihara S., Ouchi N., et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 2006, 47:1108-1116.
12. Tan K.C., Xu A., Chow W.S., et al. Hypoadiponectinemia is associated with impaired endothelium dependent vasodilation. J Clin Endocrinol Metab 2004, 89:765-769.
13. Goodfriend T.L., Ball D.L., Raff H., et al. Oxidized products of linoleic acid stimulate adrenal steroidogenesis. Endocr Res 2002, 28:325-330.
14. Kim J.-R., Kiefe C.I., Liu K., et al. Heart rate and subsequent blood pressure in young adults: the CARDIA Study. Hypertension 1999, 33:640-646.
15. Esler M. The sympathetic system and hypertension. Am J Hypertens 2000, 13:99S-105S.
16. Izzo J.L. The sympathetic nervous system in acute and chronic blood pressure elevation. Hypertension: A Companion to Brenner & Rector's The Kidney 2005, 60-76. WB Saunders, Philadelphia, PA. 2nd ed. S. Oparil, M.A. Weber (Eds.).
17. Guyenet P.G. The sympathetic control of blood pressure. Nat Rev Neurosci 2006, 5:335-346.
18. Westfall T.C., Westfall D.P. Adrenergic agonists and antagonists. Goodman & Gilman's The Pharmacological Basis of Therapeutics 2006, 237-296. McGraw-Hill Professional, New York, NY. 11th ed. L.L. Brunton, J.S. Lazo, K.L. Parker (Eds.).
19. Spruill T.M. Chronic psychosocial stress and hypertension. Curr Hypertens Rep 2010, 12:10-16.
20. Calhoun D.A., Mutinga M.L., Collins A.S., et al. Normotensive blacks have heightened sympathetic response to cold pressor test. Hypertension 1993, 22:801-805.
21. Cook N.R., Cutler J.A., Obarzanek E., et al. Long-term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the Trials of Hypertension Prevention (TOHP). BMJ 2007, 334:885-888.
22. Cook N.R., Obarzanek E., Cutler J.A., et al. Joint effects of sodium and potassium intake on subsequent cardiovascular disease: the Trials of Hypertension Prevention follow-up study. Arch Intern Med 2009, 169:32-40.
23. He F.J., MacGregor G.A. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. J Hum Hypertens 2002, 16:761-770.
24. Pimenta E., Gaddam K.K., Oparil S., et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009, 54:475-481.
25. Acelajado M.C., Oparil S. Hypertension in the elderly. Clin Geriatr Med 2009, 25:391-412.
26. Coylewright M., Reckelhoff J.E., Ouyang P. Menopause and hypertension an age-old debate. Hypertension 2008, 51:952-959.
27. Anderson D.E., Fedorova O.V., Morrell C.H., et al. Endogenous sodium pump inhibitors and age-associated increases in salt sensitivity of blood pressure in normotensives. Am J Physiol Regul Integr Comp Physiol 2008, 294:R1248-R1254.
28. Sanders P.W. Vascular consequences of dietary salt intake. Am J Physiol Renal Physiol 2009, 297:F237-F243.
29. Dahly A.J., Hoagland K.M., Flasch A.K., et al. Antihypertensive effects of chronic anti-TGF-β-antibody therapy in Dahl S rats. Am J Physiol Regul Integr Comp Physiol 2002, 283:R757-R767.
30. Dimmeler S., Fleming I., Fisslthaler B., et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999, 399:601-605.
31. Briones A.M., Arribas S.M., Salaices M. Role of extracellular matrix in vascular remodeling of hypertension. Curr Opin Nephrol Hypertens 2010, 19:187-194.
32. Mendelsohn M.E. In hypertension, the kidney is not always the heart of the matter. J Clin Invest 2005, 115:840-844.
33. Sankaranarayanan A., Raman G., Busch C., et al. Naphtho[1,2-d] thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol 2009, 75:281-295.
34. Wirth A. Rho kinase and hypertension. Biochim Biophys Acta 2010, 1802:1276-1284.
35. Crowley S.D., Gurley S.B., Oliverio M.I., et al. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J Clin Invest 2005, 115:1092-1099.
36. Johnson R.J., Feig D.I., Nakagawa T., et al. Pathogenesis of essential hypertension: historical paradigms and modern insights. J Hypertens 2008, 26:381-391.
37. Franse L.V., Pahor M., Di Bari M., et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program. J Hypertens 2000, 18:1149-1154.
38. Hoieggen A., Alderman M.A., Kjeldsen S.E., et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004, 65:1014-1019. for the LIFE Study Group.
39. Mazzali M., Kanellis J., Han L., et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002, 282:F991-997.
40. Corry D.B., Eslami P., Yamamoto K., et al. Uric acid stimulates vascular smooth muscle proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008, 26:269-275.
41. Sautin Y.Y., Nakagawa T., Zharikov S., et al. Adverse effects of the classical antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007, 293:C584-C596.
42. Kanbay M., Ozkara A., Selcoki Y., et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007, 39:1227-1233.
43. Walsh M.B., Donnelly T., Lyons D. Impaired endothelial nitric oxide bioavailability: a common link between aging, hypertension and atherogenesis?. J Am Geriatr Soc 2009, 57:140-145.
44. Franklin S.S., Lopez V.A., Wong N.D., et al. Single versus combined blood pressure components and risk for CVD. The Framingham Heart Study. Circulation 2009, 119:243-250.
45. Nguyen G., Delarue F., Burckle C., et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular response to renin. J Clin Invest 2002, 109:1417-1427.
46. Varagic J., Trask A.J., Jessup J.A., et al. New angiotensins. J Mol Med 2008, 86:663-671.
47. Carey R.M., Siragy H.M. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 2003, 24:261-271.
48. Ichihara A., Kaneshiro Y., Suzuki F. Prorenin receptor blockers: effects on cardiovascular complications of diabetes and hypertension. Expert Opin Investig Drugs 2006, 15:1137-1139.
49. Datla S.R., Griendling K.K. Reactive oxygen species, NADPH oxidases and hypertension. Hypertension 2010, 56:325-330.
50. Mihailidou A., Mardini M., Funder J.W. Rapid, nongenomic effects of aldosterone in the heart mediated by epsilon protein kinase C. Endocrinology 2004, 145:773-780.
51. Tomaschitz A., Pilz S., Ritz E., et al. Aldosterone and arterial hypertension. Nat Rev Endocrinol 2010, 6:83-93.
52. Kagiyama S., Matsumura K., Goto K., et al. Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type 1a receptor knockout mice. Regul Pept 2010, 160:133-139.
53. Nishizaka M.K., Zaman M.A., Calhoun D.A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925-930.
54. Gaddam K.K., Nishizaka M.K., Pratt-Ubunama M.N., et al. Characterization of resistant hypertension. Association between resistant hypertension, aldosterone, and persistent intravascular expansion. Arch Intern Med 2008, 168:1159-1164.
55. Cooper S.A., Whaley-Connell A., Habibi J., et al. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 2007, 293:H2009-2023.
56. Gaddam K., Corros C., Pimenta E., et al. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism. A prospective clinical study. Hypertension 2010, 55:1137-1142.
57. Schulz E., Jansen T., Wenzel P., et al. Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal 2008, 10:1115-1126.
58. Holowatz L.A., Kenney W.L. Up-regulation of arginase activity contributes to attenuated reflex cutaneous vasodilatation in hypertensive humans. J Physiol 2007, 581:863-872.
59. Bagnost T., Ma L., da Silva R.F., et al. Cardiovascular effects of arginase inhibition in spontaneously hypertensive rats with fully developed hypertension. Cardiovasc Res 2010, 87:569-577.
60. Chawengsub Y., Gauthier K.M., Campbell W.B. Role of arachidonic acid lipoxygenase metabolites in the regulation of vascular tone. Am J Physiol Heart Circ Physiol 2009, 297:H495-H507.
61. Vanhoutte P.M., Feletou M., Taddei S. Endothelium-dependent contractions in hypertension. Br J Pharmacol 2005, 144:449-458.
62. Kohan D.E. Endothelin, hypertension and chronic kidney disease: new insights. Curr Opin Nephrol Hypertens 2010, 19:134-139.
63. Campese V.M., Nadim M.K. Natriuretic peptides. Hypertension: A Companion to Brenner & Rector's The Kidney 2005, 169-192. Mosby, Philadelphia, PA. 2nd ed. S. Oparil, M.A. Weber (Eds.).
64. Wang D., Oparil S., Feng J.A., et al. Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse. Hypertension 2003, 42:88-95.
65. Takimoto E., Champion H.C., Li M., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005, 11:214-222.
66. Carretero O., Yang X.P., Rhaleb N.E. The kallikrein-kinin system as a regulator of cardiovascular and renal function. Hypertension: A Companion to Brenner & Rector's The Kidney 2005, 203-218. Mosby, Philadelphia, PA. 2nd ed. S. Oparil, M.A. Weber (Eds.).
67. Watson R.E., DiPette D.J., Supowit S.C., et al. Vasodilator peptides: CGRP, substance P, and adrenomedullin. Hypertension: A Companion to Brenner & Rector's The Kidney 2005, 193-202. Mosby, Philadelphia, PA. 2nd ed. S. Oparil, M.A. Weber (Eds.).